OS001
Cystic Fibrosis
PreclinicalActive
Key Facts
About OmniSpirant Therapeutics
OmniSpirant Therapeutics is a private, preclinical-stage biotech leveraging its proprietary OmniSome exosome platform to create inhaled regenerative gene therapies for respiratory diseases. The platform combines the natural delivery efficiency of stem cell-derived extracellular vesicles with engineered mucus-penetrating and cell-targeting capabilities. With lead programs in cystic fibrosis (OS001) and lung cancer (OS003), the company is positioned in the high-growth fields of advanced drug delivery and gene therapy. Its partnership with Aerogen for nebulizer delivery and the platform's potential applicability beyond the lungs present significant opportunities for expansion.
View full company profileTherapeutic Areas
Other Cystic Fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| CB-280 | Calithera Biosciences | Preclinical/Phase 1 |
| Ensifentrine | Verona Pharma | Phase 2 |
| ALTA Drug Series | Alteron Therapeutics | Preclinical |
| ColiFin® | Spexis | Marketed (EU) |
| Cystic fibrosis (CRISPR) | GeneToBe | Discovery |
| Cystic fibrosis (undisclosed) | GeneToBe | Early Discovery |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| Targeted Lung Delivery | Nanite | Pre-clinical |
| CFTR 100+ Panel | Agena Bioscience | Commercial |
| RIG-301 CFTR | RIGImmune | Pre-clinical |
| CBN-101 | Carbon Biosciences | Preclinical |
| RESP® Biosensor Evaluation (with Rutgers Health) | Strados Labs | Research Study |